These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9443125)
21. Pancreatic Enzyme Replacement Therapy and Coefficient of Fat Absorption in Children and Adolescents With Cystic Fibrosis. Woestenenk JW; van der Ent CK; Houwen RH J Pediatr Gastroenterol Nutr; 2015 Sep; 61(3):355-60. PubMed ID: 25782658 [TBL] [Abstract][Full Text] [Related]
22. Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. Ramsden WH; Moya EF; Littlewood JM Arch Dis Child; 1998 Oct; 79(4):339-43. PubMed ID: 9875045 [TBL] [Abstract][Full Text] [Related]
23. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Konstan MW; Stern RC; Trout JR; Sherman JM; Eigen H; Wagener JS; Duggan C; Wohl ME; Colin P Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1365-71. PubMed ID: 15606399 [TBL] [Abstract][Full Text] [Related]
24. High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial. Lancellotti L; Cabrini G; Zanolla L; Mastella G J Pediatr Gastroenterol Nutr; 1996 Jan; 22(1):73-8. PubMed ID: 8788291 [TBL] [Abstract][Full Text] [Related]
25. The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature. Pawel BR; de Chadarévian JP; Franco ME Hum Pathol; 1997 Apr; 28(4):395-9. PubMed ID: 9104936 [TBL] [Abstract][Full Text] [Related]
26. Comparison of weight-based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis. Beker LT; Fink RJ; Shamsa FH; Chaney HR; Kluft J; Evans E; Schidlow DV J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):191-7. PubMed ID: 7815242 [TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. Heubi JE; Schaeffer D; Ahrens RC; Sollo N; Strausbaugh S; Graff G; Jain R; Witte S; Forssmann K J Pediatr; 2016 Sep; 176():156-161.e1. PubMed ID: 27297209 [TBL] [Abstract][Full Text] [Related]
28. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. Borowitz D; Stevens C; Brettman LR; Campion M; Wilschanski M; Thompson H; J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):248-57. PubMed ID: 22266487 [TBL] [Abstract][Full Text] [Related]
29. High strength pancreatic exocrine enzyme capsules associated with colonic strictures in patients with cystic fibrosis: "more is not necessarily better". Lebenthal E J Pediatr Gastroenterol Nutr; 1994 May; 18(4):423-5. PubMed ID: 8071775 [No Abstract] [Full Text] [Related]
30. Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis. Chiuve SE; Fife D; Leitz G; Peterson C; Campbell NM; Rennig A; Rodrigues L; Decktor D; Dowd C; Marshall BC; Borowitz D J Cyst Fibros; 2023 Nov; 22(6):1017-1023. PubMed ID: 37880023 [TBL] [Abstract][Full Text] [Related]
31. Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis. Morrison G; Morrison JM; Redmond AO; Byers CA; McCracken KJ; Dodge JA; Guilford SA; Bowden MW Aliment Pharmacol Ther; 1992 Oct; 6(5):549-55. PubMed ID: 1420747 [TBL] [Abstract][Full Text] [Related]
32. Fibrosing colonopathy revealing cystic fibrosis in a neonate before any pancreatic enzyme supplementation. Serban DE; Florescu P; Miu N J Pediatr Gastroenterol Nutr; 2002 Sep; 35(3):356-9. PubMed ID: 12352527 [TBL] [Abstract][Full Text] [Related]
33. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients. Kishk OA; Kim I; Cheng C; Summan M; Muñoz MA Pediatr Nephrol; 2024 Aug; 39(8):2429-2433. PubMed ID: 38462547 [TBL] [Abstract][Full Text] [Related]
34. Fibrosing colonopathy in children with cystic fibrosis. Littlewood JM Postgrad Med J; 1996 Mar; 72(845):129-30. PubMed ID: 8731700 [No Abstract] [Full Text] [Related]
35. [Fibrosing colonopathy, an increasing complication of cystic fibrosis]. Gómez Morales L; García Morillo S; Herrera Justiniano JM; Avila Polo R Rev Clin Esp; 2011 Jan; 211(1):63-4. PubMed ID: 21194685 [No Abstract] [Full Text] [Related]
36. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. Borowitz D; Goss CH; Limauro S; Konstan MW; Blake K; Casey S; Quittner AL; Murray FT J Pediatr; 2006 Nov; 149(5):658-662. PubMed ID: 17095338 [TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. Kraisinger M; Hochhaus G; Stecenko A; Bowser E; Hendeles L J Clin Pharmacol; 1994 Feb; 34(2):158-66. PubMed ID: 8163716 [TBL] [Abstract][Full Text] [Related]
39. The role of MRI in the intestinal complications in cystic fibrosis. Almberger M; Iannicelli E; Antonelli M; Matrunola M; Cimino G; Passariello R Clin Imaging; 2001; 25(5):344-8. PubMed ID: 11682294 [TBL] [Abstract][Full Text] [Related]